News

A closer look at how anti-smoking campaigns have changed over the years, in India and around the world, shaped by evolving ...
SPY001 is a novel, half-life extended α4β7 antibody in development for the treatment of Inflammatory Bowel Disease (IBD) SPY001 pharmacokinetic (PK) data up to eight months continues to support ...
SPY001 is a novel, half-life extended α4β7 antibody in development for the treatment of Inflammatory Bowel Disease (IBD) Skip to main content You have permission to edit this article. Edit Close ...
Details of the oral and poster presentation are as follows: Presentation Title: GT-02287, A Clinical-stage Allosteric GCase Modulator For The Treatment Of Parkinson’s Disease, Protects ...
Gain Therapeutics is presenting their lead drug candidate, GT-02287, for Parkinson's disease at the IAPRD conference. When is the oral poster presentation scheduled? The oral poster presentation ...
Session: Oral Poster Presentation – Guided Poster TourSession ... is in clinical development for the treatment of Parkinson’s disease (PD) with or without a GBA1 mutation.
Gain Therapeutics' lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson's disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant ...
The minor party’s posters featured the slogan: “Change is Possible ... “When a tree’s bark is penetrated, it is exposed to disease and insect infestation, so screwing nails into a tree ...
Balmukundacharya, 48, has been booked by the police on Friday night on a complaint alleging that he along with a group of his supporters raised slogans and pasted offensive posters in the ... leading ...
It was the last day of his multistate Make American Healthy Again tour, designed to highlight various aspects of Mr. Kennedy’s plan to fight chronic disease, such as healthy school lunches and ...
For more information about Digestive Disease Week please visit the conference website. Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel ...